• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Entegrion lands $43.7 million DOD deal | Funding Roundup

Entegrion lands $43.7 million DOD deal | Funding Roundup

October 5, 2011 By MassDevice staff

Entegrion

Entegrion landed a $43.7 million dollar contract with the Dept. of Defense for its Resusix proprietary dehydrated pathogen-inactivated human plasma.

Resusix holds promise as a substitute for fresh frozen plasma in certain situations. The Defense Dept. contract will fund Resusix’s development through Phase III clinical trials and biological license application.

"Our focus is to offer a safer and more effective alternative for frozen blood plasma,which often is not readily available in austere and remote locations." Joseph DaCorta, Entegrion’s Chief Technology office, said in prepared remarks. "In addition, Resusix has tremendous potential for serving unmet medical needs in global health settings."

Sign up to get our free newsletters delivered right to your inbox.

The Durham, N.C.-based company expects ten to 15 clinical investigation sites to participate in each phase of the product’s clinical development.

Funding

Here’s a roundup of other dealflow and investment news:

  • Bridge Bank provides $2.5 million credit line to Image Stream Medical
    Bridge Capital Holdings (NASDAQ: BBNK) subsidiary, Bridge Bank, provided a $2.5 million line of credit to Image Stream Medical.
    Read more
  • Spire Biomedical awarded NIH grant for dental arch wire coatings
    Spire Biomedical landed a nine-month Small Business Innovation Research grant from the National Institute of Dental and Craniofacial Research.
    Read more
  • TearScience lands $15 million for dry eye treatment
    Medical device company Tear Science secured $15 million in debt financing to further its dry eye treatments.
    Read more
  • LambdaVision Inc receives pre-seed financing for retinal implant
    UConn-grown medical device startup, Lambda Vision Inc. received $40,000 in financing from Connecticut Innovations to develop a retinal implant.
    Read more
  • Touch Bionics lands funding for global expansion
    Prosthetic tech company Touch Bionics secured nearly $4 million to finance its global expansion.
    Read more
  • NxThera raises $21.6 million in series B financing
    Men’s health company NxThera raised $21.6 million in series B financing for its Rezum vapor ablation device.
    Read more
  • IPG secures three-fold credit increase from Silicon Valley Bank
    Implantable Provider Group secured a three-fold increase in their line of credit arrangement with Silicon Valley Bank.
    Read more
  • CV Ingenuity raises $16 million in Series B
    Privately-held CV Ingenuity raised $16 million in Series B financing round. Investors were led by VC New Enterprise Associates.
    Read more
  • BARDA funds development of five radiation protection drugs
    The U.S. Department of Health’s Biomedical Advanced Research and Development Authority handed out development contracts totaling $56.3 million for the treatment of injuries related to radiation syndrome.
    Read more

Filed Under: Blood Management, Funding Roundup, News Well Tagged With: defensedepartment, Dept. of Health & Human Services (HHS), Entegrion Inc., Image Stream Medical Inc., NxThera Inc., TearScience

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy